Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)β’ Click on a phase to view related trials
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
- Conditions
- Actinic Keratosis
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- DUSA Pharmaceuticals, Inc.
- Registration Number
- NCT03024060
- Locations
- πΊπΈ
Therapeutics Clinical Research, San Diego, California, United States
πΊπΈAltman Dermatology Associates, Arlington Heights, Illinois, United States
πΊπΈShideler Clinical Research Center, Carmel, Indiana, United States
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
- Conditions
- Actinic Keratosis
- Interventions
- Drug: Topical Solution VehicleDevice: IBL 10 mWDevice: IBL 20 mWProcedure: Microneedle lesion preparation
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- DUSA Pharmaceuticals, Inc.
- Target Recruit Count
- 137
- Registration Number
- NCT02632110
- Locations
- πΊπΈ
UCSD Dermatology, San Diego, California, United States
πΊπΈTherapeutics Clinical Research, San Diego, California, United States
πΊπΈMOORE Clinical Research, Inc, Brandon, Florida, United States
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
- Conditions
- Keratosis, Actinic
- Interventions
- Drug: Aminolevulinic Acid (ALA)Device: BLU-U
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- DUSA Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02628236
- Locations
- πΊπΈ
DermResearch, Inc., Austin, Texas, United States
πΊπΈJ&J Studies, Inc, College Station, Texas, United States
Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick
- Conditions
- Keratosis, Actinic
- Interventions
- Drug: Aminolevulinic Acid (ALA)Device: BLU-U
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- DUSA Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT02281136
- Locations
- πΊπΈ
Therapeutics Clinical Research, San Diego, California, United States
πΊπΈShideler Clinical Research Center, Carmel, Indiana, United States
πΊπΈDermResearch, Inc., Austin, Texas, United States
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
- Conditions
- Actinic Keratosis
- Interventions
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- DUSA Pharmaceuticals, Inc.
- Target Recruit Count
- 166
- Registration Number
- NCT02239679
- Locations
- πΊπΈ
UCSD Dermatology, San Diego, California, United States
πΊπΈTherapeutics Clinical Research, San Diego, California, United States
πΊπΈAltman Dermatology Associates, Arlington Heights, Illinois, United States
- Prev
- 1
- 2
- 3
- Next